Nasdaq · Common stock
Vogenx (VOGX)
$17.34 −$0.11 (−0.63%)
- Day’s range
- $15.01–$17.63
- Volume
- 105,988
VOGX price history
VOGX closed at $17.34 on Oct. 26, 2026. Over the past year, its daily close ranged from $13.00 on Aug. 12, 2026 to $34.13 on Sept. 17, 2026.
Data table: VOGX daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $17.34 |
| Oct. 23, 2026 | $17.45 |
| Oct. 22, 2026 | $19.08 |
| Oct. 21, 2026 | $20.39 |
| Oct. 20, 2026 | $18.75 |
| Oct. 19, 2026 | $15.92 |
| Oct. 16, 2026 | $14.53 |
| Oct. 15, 2026 | $16.05 |
| Oct. 14, 2026 | $16.10 |
| Oct. 13, 2026 | $16.76 |
| Oct. 12, 2026 | $17.14 |
| Oct. 9, 2026 | $17.56 |
| Oct. 8, 2026 | $17.49 |
| Oct. 7, 2026 | $16.16 |
| Oct. 6, 2026 | $16.39 |
| Oct. 5, 2026 | $17.15 |
| Oct. 2, 2026 | $18.23 |
| Oct. 1, 2026 | $20.06 |
| Sept. 30, 2026 | $22.79 |
| Sept. 29, 2026 | $24.32 |
| Sept. 28, 2026 | $22.00 |
| Sept. 25, 2026 | $22.73 |
| Sept. 24, 2026 | $24.20 |
| Sept. 23, 2026 | $26.86 |
| Sept. 22, 2026 | $26.57 |
| Sept. 21, 2026 | $29.50 |
| Sept. 18, 2026 | $32.50 |
| Sept. 17, 2026 | $34.13 |
| Sept. 16, 2026 | $33.39 |
| Sept. 15, 2026 | $32.21 |
| Sept. 14, 2026 | $32.42 |
| Sept. 11, 2026 | $32.71 |
| Sept. 10, 2026 | $29.86 |
| Sept. 9, 2026 | $29.80 |
| Sept. 8, 2026 | $32.00 |
| Sept. 4, 2026 | $31.73 |
| Sept. 3, 2026 | $32.15 |
| Sept. 2, 2026 | $32.10 |
| Sept. 1, 2026 | $33.13 |
| Aug. 31, 2026 | $34.00 |
| Aug. 28, 2026 | $33.96 |
| Aug. 27, 2026 | $33.63 |
| Aug. 26, 2026 | $32.88 |
| Aug. 25, 2026 | $31.53 |
| Aug. 24, 2026 | $30.73 |
| Aug. 21, 2026 | $29.52 |
| Aug. 20, 2026 | $23.65 |
| Aug. 19, 2026 | $23.16 |
| Aug. 18, 2026 | $19.75 |
| Aug. 17, 2026 | $15.75 |
| Aug. 14, 2026 | $14.78 |
| Aug. 13, 2026 | $14.09 |
| Aug. 12, 2026 | $13.00 |
Key figures
- Average daily volume
- 166,588Past 3 months
- Market value
- $257.6M
- Dividend yield
- —
Price change
- 1 month
- −23.71%
What Wall Street says about VOGX
In the past 90 days, Wall Street firms published 2 rating or price-target actions on VOGX: 2 new ratings.
| Action | Rating | |||
|---|---|---|---|---|
| WBB Securities | Initiates coverage | Speculative buy | $42 | |
| Jones Trading | Initiates coverage | Buy | $55 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Vogenx Inc Common Stock
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
- Headquarters
- Raleigh, N.C.
- Employees
- 5
- Listed
- Aug. 12, 2026
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about VOGX is on the site yet.